Governing Body Fellow hails breakthrough in trials for incurable disease

Published on
Monday 9 May 2022
Health & Medicine

Professor Jagdeep Nanchahal, a surgeon scientist at Oxford’s Kennedy Institute of Rheumatology and Governing Body Fellow at Wolfson leads breakthrough trials.

A clinical trial taking place at Oxford and Edinburgh Universities has found that a drug currently given to patients suffering from rheumatoid arthritis appeared to drive Dupuytren’s disease (an incurable condition which causes hand deformaties by bending the fingers firmly into the palm) into reverse when used early on.

This result has been described as a “gamechanger for patients suffering from the disease.  When speaking to The Guardian, Govering Body Fellow and surgical scientist Professor Jagdeep Nanchahal who led the trial at Oxford’s Kennedy Institute of Rheumatology said “we are very keen to pursue this, This is a very safe drug and it’s important patients can access a treatment if it’s likely to be effective”.

You can read the full article here.